CB2 Insights (CSE:CBII) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, is pleased to announce it has commenced trading on the Canadian Securities Exchange (CSE) under the symbol “CBII”.

“At CB2, we have been focused on bringing a heightened level of objective, actionable insights to the medical cannabis space,” said Prad Sekar, Chief Executive Officer, CB2 Insights.  “We are thrilled to be bringing CB2 Insights to the public markets and are confident that the CSE will give us a solid foundation to build on our current growth trajectory and provide additional exposure to new shareholders.”


CB2 Insights was first established in 2014 as MVC Technologies and has become a global leader in data-driven software and services, helping to better identify the efficacy of cannabinoid therapy and further mainstream cannabis into traditional healthcare.  The Company manages several sub-brands in order to provide various service offerings throughout the entire medical cannabis value chain including Canna Care Docs, Sail Cannabis and TokeIn.

About CB2 Insights

CB2 Insights has a mission to mainstream medical cannabis into traditional healthcare. We do so by gathering data and creating objective real-world evidence through our proprietary software and service brands. Using clinical management and data collection software at the point-of-care, CB2 Insights and its group of sub-brands has become a leading force behind bringing traditional healthcare protocols to the rapidly evolving global cannabis industry.

For more information please visit www.cb2insights.com.

For Investor Inquiries
Sophic Capital
1.647.362.8286
investors@cb2insights.com

For Media Inquiries:
Kate Tumino / Brittany Tibaldi
KCSA Strategic Communications
ktumino@kcsa.com / btibaldi@kcsa.com

Click here to connect with CB2 Insights (CSE:CBII) for an Investor Presentation.

Source: www.globenewswire.com

Both locations expand access to the state’s widest-ranging inventory of medical cannabis products for Central Florida patients

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of two brand-new Central Florida dispensaries. The new Clearwater and Tampa locations mark the Company’s 81 st and 82 nd nationwide, respectively, widening patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the appointment of Bart Oates Esq., President of the NFL Alumni Association, to its Advisory Board.

Philip Young, CEO and Director of Lobe, stated, “We are honored to welcome Bart to our Advisory Board. His first-hand experience on and off the field are tremendously valuable as we continue our research involving mild traumatic brain injuries and PTSD. These issues are prevalent in contact sports and we believe that athletes will play a prominent role in the continued acceptance of psychedelic medicines as legitimate treatment. We look forward to working with Bart as we seek to forge long-term strategic relationships.”

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that it has submitted its dossier to the United Kingdom’s Regulatory Food Safety Agency (the “FSA”).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005322/en/

Keep reading... Show less